cardiovascular-agents and Arrhythmogenic-Right-Ventricular-Dysplasia

Diagnostics of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) are complex, and based on the 2010 Task Force document including different diagnostic modalities. However, recommendations for clinical management and follow-up of patients with ARVC and their relatives are sparse. This paper aims to give a practical overview of management strategies, risk stratification, and selection of appropriate therapies for patients with ARVC and their family members.. This paper summarizes follow-up and treatment strategies in ARVC patients in the Nordic countries. The author group represents cardiologists who are actively involved in the Nordic ARVC Registry which was established in 2009, and contains prospectively collected clinical data from more than 590 ARVC patients from Denmark, Norway, Sweden, and Finland.. Different approaches of management and follow-up are required in patients with definite ARVC and in genetic-mutation-positive family members. Furthermore, ARVC patients with and without implantable cardioverter defibrillators (ICDs) require different follow-up strategies.. Careful follow-up is required in patients with ARVC diagnosis to evaluate the need of anti-arrhythmic therapy and ICD implantation. Mutation-positive family members should be followed regularly for detection of early disease and risk stratification of ventricular arrhythmias.

Topics: Arrhythmogenic Right Ventricular Dysplasia; Cardiovascular Agents; Catheter Ablation; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Countershock; Genetic Predisposition to Disease; Humans; Pedigree; Phenotype; Predictive Value of Tests; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Treatment Outcome

Topics: Anticoagulants; Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Benzazepines; Bradycardia; Cardiovascular Agents; Heart Diseases; Hemorrhage; Humans; Ivabradine; Point-of-Care Systems

Cardiomyopathy is a generic term for any heart disease in which the heart muscle is involved and functions abnormally. Recent developments and ongoing research in cardiology have led to descriptions of 3 previously less recognized or incompletely characterized cardiomyopathies. These entities are being increasingly noticed in adult patient populations. Primary care providers and cardiovascular specialists need to be aware of the clinical features of these illnesses and the best strategies for diagnosis and management. We have discussed the causes and diagnostic methods for these newly described cardiomyopathies and ways to manage them.

Topics: Adolescent; Adult; Aged; Arrhythmogenic Right Ventricular Dysplasia; Cardiovascular Agents; Female; Humans; Middle Aged; Takotsubo Cardiomyopathy; Ventricular Dysfunction, Left